Stock Track | Summit Therapeutics Soars 9.06% in Pre-market on Positive Lung Cancer Drug Trial Results

Stock Track06-01

Summit Therapeutics PLC (SMMT) stock soared 9.06% in pre-market trading on Monday, reflecting significant investor optimism following a major clinical development announcement.

The sharp increase is attributed to the company's presentation of positive Phase 3 HARMONi-6 trial results for its investigational drug ivonescimab at the ASCO 2026 conference. The data showed that the PD-1/VEGF bispecific antibody, combined with chemotherapy, met the prespecified interim overall survival endpoint for first-line advanced squamous non-small cell lung cancer (NSCLC).

Earlier interim results from the trial demonstrated a median progression-free survival of 11.1 months for the ivonescimab group versus 6.9 months for the control group, with a hazard ratio of 0.60. The positive survival data for the drug, which is approved in China and investigational elsewhere, has generated significant investor optimism regarding its potential market success.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158873376?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 16:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158873376","market":"nz","top_or_hot":-1,"title":"Stock Track | Summit Therapeutics Soars 9.06% in Pre-market on Positive Lung Cancer Drug Trial Results","media":"Stock Track","content":"<p>Summit Therapeutics PLC (SMMT) stock soared 9.06% in pre-market trading on Monday, reflecting significant investor optimism following a major clinical development announcement.</p><p>The sharp increase is attributed to the company's presentation of positive Phase 3 HARMONi-6 trial results for its investigational drug ivonescimab at the ASCO 2026 conference. The data showed that the PD-1/VEGF bispecific antibody, combined with chemotherapy, met the prespecified interim overall survival endpoint for first-line advanced squamous non-small cell lung cancer (NSCLC).</p><p>Earlier interim results from the trial demonstrated a median progression-free survival of 11.1 months for the ivonescimab group versus 6.9 months for the control group, with a hazard ratio of 0.60. The positive survival data for the drug, which is approved in China and investigational elsewhere, has generated significant investor optimism regarding its potential market success.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Summit Therapeutics Soars 9.06% in Pre-market on Positive Lung Cancer Drug Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Summit Therapeutics Soars 9.06% in Pre-market on Positive Lung Cancer Drug Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-01 16:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Summit Therapeutics PLC (SMMT) stock soared 9.06% in pre-market trading on Monday, reflecting significant investor optimism following a major clinical development announcement.</p><p>The sharp increase is attributed to the company's presentation of positive Phase 3 HARMONi-6 trial results for its investigational drug ivonescimab at the ASCO 2026 conference. The data showed that the PD-1/VEGF bispecific antibody, combined with chemotherapy, met the prespecified interim overall survival endpoint for first-line advanced squamous non-small cell lung cancer (NSCLC).</p><p>Earlier interim results from the trial demonstrated a median progression-free survival of 11.1 months for the ivonescimab group versus 6.9 months for the control group, with a hazard ratio of 0.60. The positive survival data for the drug, which is approved in China and investigational elsewhere, has generated significant investor optimism regarding its potential market success.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMMT","symbol_name":"Summit Therapeutics PLC","start_time":0,"source_url":"","article_id":"1158873376","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158873376","pubTimestamp":1780301109,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Summit Therapeutics PLC (SMMT) stock soared 9.06% in pre-market trading on Monday, reflecting significant investor optimism following a major clinical development announcement.The sharp increase is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMMT":"Summit Therapeutics PLC"},"translate_title":"个股追踪|肺癌药物试验结果积极Summit Therapeutics盘前大涨9.06%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1},"content_text":"Summit Therapeutics PLC (SMMT) stock soared 9.06% in pre-market trading on Monday, reflecting significant investor optimism following a major clinical development announcement.The sharp increase is attributed to the company's presentation of positive Phase 3 HARMONi-6 trial results for its investigational drug ivonescimab at the ASCO 2026 conference. The data showed that the PD-1/VEGF bispecific antibody, combined with chemotherapy, met the prespecified interim overall survival endpoint for first-line advanced squamous non-small cell lung cancer (NSCLC).Earlier interim results from the trial demonstrated a median progression-free survival of 11.1 months for the ivonescimab group versus 6.9 months for the control group, with a hazard ratio of 0.60. The positive survival data for the drug, which is approved in China and investigational elsewhere, has generated significant investor optimism regarding its potential market success.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158873376","isCrawlerRequest":true}